20240009283. Compositions Of Engineered Human Arginases And Methods For Treating Cancer simplified abstract (Aerase, Inc.)
Contents
Compositions Of Engineered Human Arginases And Methods For Treating Cancer
Organization Name
Inventor(s)
George Georgiou of Austin TX (US)
Everett Stone of Austin TX (US)
Compositions Of Engineered Human Arginases And Methods For Treating Cancer - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240009283 titled 'Compositions Of Engineered Human Arginases And Methods For Treating Cancer
Simplified Explanation
The abstract of the patent application describes compositions and methods for the treatment of cancer, specifically cancers that lack or have low levels of argininosuccinate synthetase. The invention involves the use of enzymes that deplete l-arginine in serum to treat these types of cancers. One embodiment of the invention includes an arginase protein, such as human arginase I protein, with at least one amino acid substitution and a metal cofactor. This modified protein has increased catalytic activity compared to the native human arginase I.
- Compositions and methods for treating cancer are described in the patent application.
- The invention focuses on cancers that do not express or have low levels of argininosuccinate synthetase.
- Enzymes that deplete l-arginine in serum are used in the treatment.
- An arginase protein, like human arginase I, with amino acid substitutions and a metal cofactor is included in the invention.
- The modified arginase protein has increased catalytic activity compared to the native protein.
Potential Applications:
- Treatment of cancers that lack or have low levels of argininosuccinate synthetase.
- Targeted therapy for specific types of cancer.
- Alternative treatment option for patients who do not respond to conventional therapies.
Problems Solved:
- Lack of effective treatment options for cancers deficient in argininosuccinate synthetase.
- Limited efficacy of conventional cancer therapies in certain cases.
- Need for targeted therapies that specifically address the molecular characteristics of cancer cells.
Benefits:
- Improved treatment outcomes for cancers lacking argininosuccinate synthetase.
- Potential for personalized medicine by targeting specific molecular deficiencies in cancer cells.
- Possibility of overcoming resistance to conventional cancer therapies.
- Reduced side effects compared to traditional treatments.
Original Abstract Submitted
compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete l-arginine in serum. in one embodiment, the present invention contemplates an arginase protein, such as a human arginase i protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human arginase i.
